JINGXIN(002020) 财经网·2025-04-03 03:28Core Viewpoint - Jingxin Pharmaceutical reported a revenue growth of 3.99% to 4.159 billion yuan and a net profit increase of 15.04% to 712 million yuan for the year 2024 [1] Revenue Breakdown - Finished drug revenue reached 2.522 billion yuan, up 8.42% year-on-year [1] - Raw material drug revenue was 876 million yuan, down 8.37% year-on-year [1] - Medical device revenue amounted to 687 million yuan, an increase of 7.84% year-on-year [1] Financial Metrics - Main business revenue was approximately 4.086 billion yuan with a gross margin of 50.05%, reflecting a 4.23% increase in revenue and a 0.38% decrease in gross margin compared to the previous year [2] - Other business revenue was around 727 million yuan, with a gross margin of 45.81%, showing a 7.81% decrease in revenue and a 12.00% decrease in gross margin year-on-year [2] Product Performance - The company is enhancing its product capabilities in the CNS field, with the innovative drug Jingnoning® (Dazatinib Capsules) receiving registration approval in December 2023 and set to launch in March 2024 [5] - The company has established a multi-dimensional product lineup covering CNS, cardiovascular, and digestive system diseases, with over 10 innovative drug projects in progress [6] Market Strategy - The company is focusing on expanding its innovative drug pipeline while maintaining steady operations in the generic drug business, achieving over 45% growth in outpatient market sales [6] - The company’s export revenue from formulations grew by 25% year-on-year, supported by capacity release and market expansion [6]